Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study was designed to determine the optimal dose of remifentanil that can prevent the
complications associated with the removal of LMA without delaying emergence.